A Study of Tadalafil for Duchenne Muscular Dystrophy

Status Terminated

Clinical Trial Summary

The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01865084
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Terminated
Phase	Phase 3
Start date	September 2013
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00243789` - Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy	Phase 1/Phase 2
Completed	`NCT00033189` - An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT03703882` - Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy	Phase 3
Enrolling by invitation	`NCT04626674` - A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 1
Completed	`NCT02286947` - Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT03406780` - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT01826487` - Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)	Phase 3
Completed	`NCT02710591` - Rimeporide in Patients With Duchenne Muscular Dystrophy	Phase 1
Completed	`NCT01826422` - Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients	N/A
Completed	`NCT00102453` - Pentoxifylline in Duchenne Muscular Dystrophy	Phase 1/Phase 2
Terminated	`NCT02090959` - An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy	Phase 3
Recruiting	`NCT05833633` - Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations
Completed	`NCT05209087` - Effects of Parental Influence on Physical Activity Level and Participation in Children With Duchenne Muscular Dystrophy
Completed	`NCT03789734` - Safety Study of BLS-M22 in Healthy Volunteers	Phase 1
Recruiting	`NCT05126758` - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 3
Completed	`NCT00016653` - Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy	Phase 2/Phase 3
Completed	`NCT03127241` - User-centred Assistive System for Arm Functions in Neuromuscular Subjects	N/A
Completed	`NCT03490214` - Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography	N/A
Completed	`NCT03179631` - Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy	Phase 3
Terminated	`NCT03400852` - A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy	Phase 2